Sedana Medical
Invitation to investor call related to the SESAR study results
Sedana Medical hereby invites to an investor call related to the results of the investigator initiated SESAR study today 19 March at 15:00 CET
Yesterday (18 March) the investigator initiated study ”Sevoflurane for sedation in Acute Respiratory Distress Syndrome (ARDS)”, the SESAR study, was published in The Journal of American Medicine (JAMA). Related to this, Sedena Medical invites investors and analysts to a digital presentation of the company’s assessment of the study results, and an opportunity to ask questions to the company’s CEO Johannes Doll and CMO Peter Sackey.
Date: Wednesday 19 March, 2025
Time: 15:00 CET
Link to presentation: https://www.finwire.tv/webcast/sedana-medical/investor-call/
If you wish to participate via teleconference: +46 8 5016 3827. Meeting ID: 825 3412 1573.
Welcome!
Datum | 2025-03-19, kl 11:18 |
Källa | MFN |
